Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Deferred Tax Assets (2016)

Guided Therapeutics (GTHP) has disclosed Current Deferred Tax Assets for 5 consecutive years, with $795000.0 as the latest value for Q4 2016.

  • Quarterly Current Deferred Tax Assets rose 27.0% to $795000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $795000.0 through Dec 2016, up 27.0% year-over-year, with the annual reading at $795000.0 for FY2016, 27.0% up from the prior year.
  • Current Deferred Tax Assets hit $795000.0 in Q4 2016 for Guided Therapeutics, up from $626000.0 in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $795000.0 in Q4 2016 to a low of $277000.0 in Q4 2012.
  • Historically, Current Deferred Tax Assets has averaged $490200.0 across 5 years, with a median of $466000.0 in 2014.
  • Biggest five-year swings in Current Deferred Tax Assets: increased 3.61% in 2013 and later soared 62.37% in 2014.
  • Year by year, Current Deferred Tax Assets stood at $277000.0 in 2012, then grew by 3.61% to $287000.0 in 2013, then skyrocketed by 62.37% to $466000.0 in 2014, then surged by 34.33% to $626000.0 in 2015, then increased by 27.0% to $795000.0 in 2016.
  • Business Quant data shows Current Deferred Tax Assets for GTHP at $795000.0 in Q4 2016, $626000.0 in Q4 2015, and $466000.0 in Q4 2014.